Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) EBT Margin (2016 - 2025)

Historic EBT Margin for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to 2.41%.

  • International Stem Cell's EBT Margin rose 81400.0% to 2.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.62%, marking a year-over-year increase of 73900.0%. This contributed to the annual value of 2.34% for FY2024, which is 79500.0% up from last year.
  • According to the latest figures from Q3 2025, International Stem Cell's EBT Margin is 2.41%, which was up 81400.0% from 5.27% recorded in Q2 2025.
  • In the past 5 years, International Stem Cell's EBT Margin registered a high of 5.27% during Q2 2025, and its lowest value of 36.13% during Q1 2021.
  • Moreover, its 5-year median value for EBT Margin was 6.64% (2023), whereas its average is 10.05%.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 356800bps in 2022, then plummeted by -254000bps in 2023.
  • Over the past 5 years, International Stem Cell's EBT Margin (Quarter) stood at 19.75% in 2021, then skyrocketed by 106bps to 1.15% in 2022, then tumbled by -2204bps to 24.25% in 2023, then surged by 102bps to 0.49% in 2024, then skyrocketed by 390bps to 2.41% in 2025.
  • Its EBT Margin was 2.41% in Q3 2025, compared to 5.27% in Q2 2025 and 12.02% in Q1 2025.